Semax is a synthetic ACTH(4-10) analog out of the Russian Academy of Sciences. Mechanism, BDNF work, half-life, and the gap between Russian and Western evidence. RUO.
Semax shows up in cognition stack posts as the "Russian nootropic that boosts BDNF." That framing has a real mechanism story behind it. It also has a literature posture worth being honest about: most of the corpus is Russian-language, the Western replication base is thin, and the clinical evidence sits in places PubMed doesn't fully index. This page is mechanism-through-corpus before you read anyone's stack take.
For research use only. Not medical advice. Nothing here is a recommendation to administer, prescribe, or self-administer any compound.
Semax. A synthetic heptapeptide based on the ACTH(4-10) fragment — the seven-amino-acid sequence inside adrenocorticotropic hormone that carries non-hormonal CNS activity — with a Pro-Gly-Pro tail added at the C-terminus for stability.
Mechanism class: nootropic and neurotrophic research peptide. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same program that produced Selank. Registered for clinical use in Russia, including for ischemic stroke. Not approved in the US. Not approved in the EU.
The category Semax lives in inside this newsletter: cognition and neurotrophic research peptides, alongside Selank and Cerebrolysin.
Semax inherits the part of ACTH that the brain cares about and discards the part the adrenal cortex cares about. ACTH(4-10) is the melanocortin-receptor-active core sequence; what the parent ACTH does for cortisol release lives outside this fragment. Semax keeps the central activity and adds Pro-Gly-Pro to slow degradation by aminopeptidases.
The published mechanism work — both Russian and the Western fraction that got translated — clusters around three areas:
BDNF and neurotrophic signaling. Semax administration in rodent models is associated with increased expression of brain-derived neurotrophic factor and its receptor TrkB in hippocampus and cortex. This is the "BDNF peptide" story you see referenced in stack posts. The signal is real in the rodent work; the question is downstream of that.
Dopaminergic modulation. Effects on dopamine turnover and on dopaminergic projection systems appear in the behavioral pharmacology corpus. This is part of the mechanism story behind reported attention-and-motivation effects.
Neuroprotection in ischemia models. This is the clinical use case Semax is registered for in Russia: as adjunct therapy in ischemic stroke. The mechanism work here covers free-radical handling, BDNF-mediated neuronal survival, and reduction of infarct volume in rodent middle-cerebral-artery-occlusion models.
The one-line summary the literature supports: a melanocortin-fragment peptide with a real neurotrophic signal in rodent and small-clinical work.
The one-line summary the literature does not support: a settled human nootropic with characterized long-term effects in healthy users.
Half-life. Short in plasma — minutes for the parent peptide. The Pro-Gly-Pro stabilization extends in-vivo activity but doesn't make Semax long-acting. As with Selank, behavioral effects in the published rodent work outlast plasma clearance, consistent with upstream signaling effects rather than direct sustained receptor occupancy.
Route. Intranasal is the dominant administered route across the Russian preclinical and clinical corpus. This is the registered route. Subcutaneous and intravenous administration appear in some experimental contexts (the IV route shows up in the stroke-adjunct clinical work). Oral administration is not characterized in published work — the peptide is digested.
The same honest framing applies as with Selank.
The Semax literature is heavily Russian-language and only partially indexed in Western databases. Foundational authors include Myasoedov, Ashmarin, Levitskaya, Skvortsova. The corpus spans rodent behavioral pharmacology, gene-expression work (BDNF, dopaminergic markers), and Russian clinical use in ischemic stroke and cognitive disorders.
What you can find in English on PubMed:
What you cannot easily find in English:
In the tier framework:
The honest framing: Semax has a substantive Russian academic corpus, including clinical use. The Western evidence base for the founder-operator cognition use case is thin. Both facts are true.
Field reports cluster in three areas.
Cognition and focus. The most common reported change: sustained focus on cognitively demanding tasks, often described as "task adherence" rather than "stimulant lift." The phenomenology is unlike caffeine or amphetamines; users typically don't describe euphoria or appetite suppression. Onset is reported within the first few intranasal administrations.
Mood under load. A subset of users report a flattening of low-mood states during high-stress periods. This is consistent with the BDNF-modulation mechanism story but, again, not proof in humans.
Stack pairing. Frequently reported alongside Selank in the founder-operator cohort — same Russian Academy program, complementary endpoint coverage. The Selank–Semax pair is the most-cited cognition-and-stress combo in the operator stack-post corpus.
None of this is a recommendation. Founder N=1 reports are signal, not proof.
If anyone tells you Semax is "the proven nootropic," they're skipping the part where most of the proof is in Russian and most of the human work isn't on the cohort taking it now.
Semax is one of fourteen compounds covered in The 2026 Peptide Stack Map — the lead magnet at the link below. One page per compound. Mechanism, half-life, literature, gaps.
In the Sunday issues, Semax sits inside the cognition-and-stress cluster with Selank and Cerebrolysin. Issue 1 is the entry point. The dose-citation work — what doses appear in the published Russian clinical literature — lives behind the email gate, where it belongs.
Subscribe for the weekly briefing on what's new, what survived peer review, and what's worth the vial.
Disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full FTC disclosure on the About page. For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
Subscribe to The Compound — the Sunday briefing on peptides for founder-operators. One email a week. Pull down the Stack Map on signup.
14 compounds, half-lives, and the literature — one PDF.
Download the PDF →